B. Riley Analysts Reduce Earnings Estimates for InfuSystem

InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) - B. Riley lowered their Q1 2025 EPS estimates for shares of InfuSystem in a research note issued on Tuesday, March 4th. B. Riley analyst K. Bauser now forecasts that the company will post earnings of ($0.03) per share for the quarter, down from their prior estimate of $0.04. The consensus estimate for InfuSystem's current full-year earnings is $0.15 per share. B. Riley also issued estimates for InfuSystem's Q4 2025 earnings at $0.12 EPS.

Separately, StockNews.com lowered InfuSystem from a "strong-buy" rating to a "buy" rating in a research note on Thursday, March 6th.

InfuSystem Stock Performance

Shares of INFU stock traded down $0.07 during trading hours on Friday, reaching $5.57. 209,839 shares of the company traded hands, compared to its average volume of 115,064. The firm has a 50-day moving average price of $7.87 and a 200 day moving average price of $7.59. The company has a market cap of $118.44 million, a P/E ratio of 92.85 and a beta of 1.75. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.98 and a quick ratio of 1.59. InfuSystem has a 12-month low of $5.28 and a 12-month high of $9.97.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of INFU. GSA Capital Partners LLP grew its position in InfuSystem by 23.9% in the 3rd quarter. GSA Capital Partners LLP now owns 65,680 shares of the company's stock valued at $440,000 after acquiring an additional 12,657 shares during the last quarter. Oppenheimer Asset Management Inc. grew its holdings in shares of InfuSystem by 28.0% in the third quarter. Oppenheimer Asset Management Inc. now owns 33,337 shares of the company's stock worth $223,000 after purchasing an additional 7,295 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in InfuSystem in the 3rd quarter worth about $87,000. BNP Paribas Financial Markets lifted its holdings in InfuSystem by 66.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company's stock valued at $27,000 after buying an additional 1,626 shares in the last quarter. Finally, State Street Corp boosted its position in InfuSystem by 1.1% in the 3rd quarter. State Street Corp now owns 267,012 shares of the company's stock valued at $1,789,000 after buying an additional 3,019 shares during the period. Hedge funds and other institutional investors own 71.13% of the company's stock.

Remove Ads

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.